{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:17:39Z","timestamp":1791080259394,"version":"4.1.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2344,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Portal hypertension, the most important complication in patients with cirrhosis of the liver, is a serious and life-threatening disease for which there are few therapeutic options. Because angiogenesis is a pathological hallmark of portal hypertension, the goal of this study was to determine the effects of sorafenib\u2014a potent inhibitor of proangiogenic vascular endothelial growth factor receptor 2 (VEGFR-2), platelet-derived growth factor receptor \u03b2 (PDGFR-\u03b2), and Raf kinases\u2014on splanchnic, intrahepatic, systemic, and portosystemic collateral circulations in two different experimental models of portal hypertension: rats with prehepatic portal hypertension induced by partial portal vein ligation and rats with intrahepatic portal hypertension and secondary biliary cirrhosis induced by bile duct ligation. Such a comprehensive approach is necessary for any translational research directed toward defining the efficacy and potential clinical application of new therapeutic agents. Sorafenib administered orally once a day for 2 weeks in experimental models of portal hypertension and cirrhosis effectively inhibited VEGF, PDGF, and Raf signaling pathways, and produced several protective effects by inducing an approximately 80% decrease in splanchnic neovascularization and a marked attenuation of hyperdynamic splanchnic and systemic circulations, as well as a significant 18% decrease in the extent of portosystemic collaterals. In cirrhotic rats, sorafenib treatment also resulted in a 25% reduction in portal pressure, as well as a remarkable improvement in liver damage and intrahepatic fibrosis, inflammation, and angiogenesis. Notably, beneficial effects of sorafenib against tissue damage and inflammation were also observed in splanchnic organs. <jats:italic toggle=\"yes\">Conclusion:<\/jats:italic> Taking into account the limitations of translating animal study results into humans, we believe that our findings will stimulate consideration of sorafenib as an effective therapeutic agent in patients suffering from advanced portal hypertension. (Hepatology 2009.)<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.22758","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T18:54:55Z","timestamp":1227639295000},"page":"1245-1256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":276,"title":["Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats #"],"prefix":"10.1097","volume":"49","author":[{"given":"Marc","family":"Mejias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Garcia-Pras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Tiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Miquel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-22-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0889-8553(21)00175-8","article-title":"Pathophysiology of portal hypertension.","volume":"21","author":"Bosch","year":"1992","journal-title":"Gastroenterol Clin North Am"},{"key":"R2-22-20241201","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1053\/j.gastro.2007.10.028","article-title":"How to prevent varices from bleeding: shades of grey. The case for nonselective beta blockers.","volume":"133","author":"Thalheimer","year":"2007","journal-title":"Gastroenterology"},{"key":"R3-22-20241201","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0092-8674(00)81810-3","article-title":"Blood vessel formation: what is its molecular basis?","volume":"87","author":"Folkman","year":"1996","journal-title":"Cell"},{"key":"R4-22-20241201","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2003.12.012","article-title":"AntiVEGF receptor2 monoclonal antibody prevents portalsystemic collateral vessel formation in portal hypertensive mice.","volume":"126","author":"Fernandez","year":"2004","journal-title":"Gastroenterology"},{"key":"R5-22-20241201","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jhep.2005.02.022","article-title":"Inhibition of VEGF receptor2 decreases the development of hyperdynamic splanchnic circulation and portalsystemic collateral vessels in portal hypertensive rats.","volume":"43","author":"Fernandez","year":"2005","journal-title":"J Hepatol"},{"key":"R6-22-20241201","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2005.09.021","article-title":"Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats.","volume":"44","author":"Angermayr","year":"2006","journal-title":"J Hepatol"},{"key":"R7-22-20241201","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/gut.2005.088013","article-title":"NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperemia in portal hypertensive rats.","volume":"56","author":"Angermayr","year":"2007","journal-title":"Gut"},{"key":"R8-22-20241201","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.21785","article-title":"Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and plateletderived growth factor blockade in rats.","volume":"46","author":"Fernandez","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R9-22-20241201","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1111\/j.1582-4934.2008.00218.x","article-title":"The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats.","volume":"12","author":"Mejias","year":"2008","journal-title":"J Cell Mol Med"},{"key":"R10-22-20241201","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 439006 exhibits broad spectrum oral antitumor activity and targets the RAFMEKERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R11-22-20241201","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clearcell renalcell carcinoma.","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R12-22-20241201","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma.","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R13-22-20241201","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/0016-5085(95)90698-3","article-title":"Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats.","volume":"108","author":"Fernandez","year":"1995","journal-title":"Gastroenterology"},{"key":"R14-22-20241201","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/hep.1840180224","article-title":"Effects of ritanserin, a selective and specific S2serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with longterm bile duct ligation.","volume":"18","author":"Fernandez","year":"1993","journal-title":"HEPATOLOGY"},{"key":"R15-22-20241201","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1001\/archsurg.1979.01370330086016","article-title":"Portal hypertension after bile duct obstruction.","volume":"114","author":"Franco","year":"1979","journal-title":"Arch Surg"},{"key":"R16-22-20241201","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1172\/JCI24282","article-title":"Liver fibrosis.","volume":"115","author":"Bataller","year":"2005","journal-title":"J Clin Invest"},{"key":"R17-22-20241201","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough.","volume":"35","author":"Wiest","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R18-22-20241201","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1002\/hep.510290621","article-title":"Increased heme oxygenase1 gene expression in liver cells and splanchnic organs from portal hypertensive rats.","volume":"29","author":"Fernandez","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R19-22-20241201","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1172\/JCI114363","article-title":"Effects of plateletderived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fatstoring cells.","volume":"84","author":"Pinzani","year":"1989","journal-title":"J Clin Invest"},{"key":"R20-22-20241201","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.21564","article-title":"Sinusoidal remodeling and angiogenesis: a new function for the liverspecific pericyte?","volume":"45","author":"Lee","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R21-22-20241201","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1124\/jpet.104.079616","article-title":"Longterm treatment of bile ductligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms.","volume":"313","author":"Biecker","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R22-22-20241201","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jhep.2006.07.030","article-title":"Lowdose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis.","volume":"45","author":"Neef","year":"2006","journal-title":"J Hepatol"},{"key":"R23-22-20241201","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1002\/hep.21921","article-title":"Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats.","volume":"46","author":"Tugues","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R24-22-20241201","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0165-2478(88)90141-1","article-title":"Interleukin 1, interleukin 6 and tumor necrosis factor in infection, inflammation and immunity.","volume":"19","author":"Bendtzen","year":"1988","journal-title":"Immunol Lett"},{"key":"R25-22-20241201","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(04)16206-5","article-title":"Serum lipopolysaccharidebinding protein prediction of severe bacterial infection in cirrhotic patients with ascites.","volume":"363","author":"Albillos","year":"2004","journal-title":"Lancet"},{"key":"R26-22-20241201","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1053\/j.gastro.2008.04.010","article-title":"Plateletderived growth factor signaling through ephrinB2 regulates hepatic vascular structure and function.","volume":"135","author":"Semela","year":"2008","journal-title":"Gastroenterology"},{"key":"R27-22-20241201","first-page":"373","article-title":"Vascular density and VEGF expression in hepatic lesions.","volume":"16","author":"Brodsky","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"key":"R28-22-20241201","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.3748\/wjg.14.2349","article-title":"Vascular endothelial growth factor attenuates hepatic sinusoidal capillarization in thioacetamideinduced cirrhotic rats.","volume":"14","author":"Xu","year":"2008","journal-title":"World J Gastroenterol"},{"key":"R29-22-20241201","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1440-1746.2006.04629.x","article-title":"Gene expression profiling in whole liver of bile duct ligated rats: VEGFA expression is upregulated in hepatocytes adjacent to the portal tracts.","volume":"22","author":"Tanaka","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R30-22-20241201","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1172\/JCI4891","article-title":"Biologic significance of angiopoietin2 expression in human hepatocellular carcinoma.","volume":"103","author":"Tanaka","year":"1999","journal-title":"J Clin Invest"},{"key":"R31-22-20241201","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0168-8278(03)00053-9","article-title":"Hepatocyte growth factor activates endothelial proangiogenic mechanisms relevant in chronic hepatitis Cassociated neoangiogenesis.","volume":"38","author":"Medina","year":"2003","journal-title":"J Hepatol"},{"key":"R32-22-20241201","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.1840170622","article-title":"Bacterial translocation in acute and chronic portal hypertension.","volume":"17","author":"GarciaTsao","year":"1993","journal-title":"HEPATOLOGY"},{"key":"R33-22-20241201","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0168-8278(96)80064-X","article-title":"Quality of life, major medical complications and hospital service utilization in patients with primary biliary cirrosis after liver transplantation.","volume":"25","author":"Navasa","year":"1996","journal-title":"J Hepatol"},{"key":"R34-22-20241201","first-page":"1388","article-title":"Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.","volume":"60","author":"Eberhard","year":"2000","journal-title":"Cancer Res"},{"key":"R36-22-20241201","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/jhep.2003.50133","article-title":"Hemodynamic response to pharmacological treatment of portal hypertension and longterm prognosis of cirrhosis.","volume":"37","author":"Abraldes","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R37-22-20241201","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2006.09.013","article-title":"Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrosis: a systematic review.","volume":"131","author":"DAmico","year":"2006","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.22758","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200904000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T13:33:52Z","timestamp":1733060032000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200904000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.22758","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}